Skip to content

AdaptHealth AHCO EV / EBITDA

EV / EBITDA at other companies

CVS Health logo
CVS HealthCVS
9.2×+2.7×
Cardinal Health logo
Cardinal HealthCAH
16.9×+4.4×
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
19×+3.3×
Aveanna Healthcare Holdings Inc. logo
Aveanna Healthcare Holdings Inc.AVAH
-2.9×
The Pennant Group, Inc. logo
The Pennant Group, Inc.PNTG
22.9×-1.7×
ResMed logo
ResMedRMD
15.2×-3.1×

Other financials

Income statement

See full
Revenue$819.8M+5.4%
Gross profit$111.5M-7.4%
Operating income$5.5M-76.3%
Net income-$16.0M-123%
EPS (diluted)-$0.12-140%

Balance sheet

See full
Cash & equivalents$48.0M-10.6%
Total debt$2.0B-4.9%
Total equity$1.5B-3.9%
Total assets$4.4B-0.3%

Cash flow

See full
Operating cash flow$93.7M-1.9%
CapEx$121.2M+26.8%
Free cash flow-$27.5M-47,297%

Valuation

See full
Market cap$1.36B+20.5%
Enterprise value$3.32B+4.3%
P/S0.4×+0.1×

Profitability

See full
Gross margin18.3%-1.6pp
Operating margin8%+6.9pp
Net margin-2.4%-5.1pp
FCF margin5.8%-2.6pp

Returns & leverage

See full
Return on equity-5.2%-10.8pp
Debt / equity1.3×0.0×
Current ratio0.9×-0.4×

Where this comes from

Calculated from AdaptHealth’s reported figures.

Based on the most recent quarter.

The official record: AdaptHealth’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about AdaptHealth's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AdaptHealth's EV / EBITDA?
AdaptHealth (AHCO) reported EV / EBITDA of 8.5× in Q1 2026.
How has AdaptHealth's EV / EBITDA changed year-over-year?
AdaptHealth's EV / EBITDA increased by 46.7% year-over-year, from 5.8× to 8.5×.
What is the long-term trend for AdaptHealth's EV / EBITDA?
Over 4 years (2020 to 2025), AdaptHealth's EV / EBITDA has grown at a -30.5% compound annual growth rate (CAGR), from 31.9× to 7.4×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.